Thermo Fisher Scientific building. Credit: Thermo Fisher Scientific.

Thermo Fisher Scientific has introduced a next-generation sequencing (NGS) panel called Oncomine Childhood Cancer Research Assay to enable the study of genetic alterations associated with paediatric and young adult cancers.

Developed in alliance with Children’s Hospital Los Angeles, the Oncomine assay is a combination of specific mutations, gene amplification and fusions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The comprehensive panel is designed to analyse 203 unique genes from various classes along with 1,700 fusion transcripts in two pools each of DNA and RNA through an NGS workflow.

“Developed in alliance with Children’s Hospital Los Angeles, the Oncomine assay is a combination of specific mutations, gene amplification and fusions.”

It can be used with the Ion Chef System to carry out automated library preparation and amplification, and Ion GeneStudio S5 Systems and the company’s Ion Reporter for performing downstream bioinformatics and reporting.

Thermo Fisher has also established the International Childhood Oncology Network (ICON) involving several academic and clinical researchers.

Members of the global community are set to exchange data, practices and experiment with protocols to advance the understanding of paediatric, childhood and young adult cancers in order to enable better management of these conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Children’s Hospital Los Angeles Center for Personalized Medicine co-director Timothy Triche said: “The Oncomine Childhood Cancer Research Assay is of particular importance because it is the first designed for all forms of childhood cancers that simultaneously detects RNA gene fusions and DNA mutations, both of which are critical in childhood cancer.

“I am also very excited by the International Childhood Oncology Network, which will allow us and its members to collect data and share our experience in an effort to drive clinical research in childhood cancer.”